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The effects of 4 days of continuous microdialysis with a small-diameter concentric-style probe on indices of striatal dopamine 
(DA) and serotonin neurotransmission were assessed. It was found that over 4 days of dialysis, there was a marked time-dependent 
decrease in the basal concentrations of 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in dialysate and in 
amphetamine-stimulated DA release. In contrast, there was no decrease in basal DA or in the ability of cocaine to elevate the 
concentration of DA in dialysate over the same period of time. There were only very modest changes in dialysate levels of the 
serotonin metabolite, 5-hydroxyindoleacetic acid (5-HIAA), relative to the marked changes in DA metabolites. It is suggested that 
4 days of continuous dialysis does not result in a non-specific decrease in diffusibility of these compounds into the dialysis probe, 
but that the changes are more likely due to probe-induced damage to the nigrostriatal DA system. It is also suggested that a 
"stable" basal concentration of DA in dialysate is an especially poor indicator of the integrity of the dopaminergic input to the 
striatum. The implications of these findings for within-subjects design microdialysis experiments are discussed. 
Introduction 
Intracerebral microdialysis has rapidly become 
a popular method for in vivo sampling of neuro- 
transmitters and their metabolites in neural tissue 
of awake, moving animals (Ungerstedt and Hall- 
str6m, 1987). The technique is relatively new, 
however, and there have been few studies de- 
signed to characterize the effects of repeated 
sampling over extended periods of time, either 
with a microdialysis probe left in place (Imperato 
and Di Chiara, 1984, 1985; Korf and Venema, 
1985; Westerink and Tuinte, 1986; Reiriz et al., 
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1989), or with multiple insertions of a probe at 
different points in time (Camp and Robinson, 
1991). Initial attempts at continuous dialysis with 
a chronically implanted dialysis probe in the ni- 
grostriatal dopamine (DA) system were not very 
encouraging. For example, Westerink and Tuinte 
(1986) reported that between 24 h and 7 days 
after probe implantation the basal concentrations 
of striatal DA and 3,4-dihydroxyphenylacetic acid 
(DOPAC) in dialysate progressively declined, as 
did the magnitude of K ÷- and amphetamine- 
stimulated DA release. This decline was at- 
tributed to cellular reactions at the probe tip, 
including gliosis, which were thought to impede 
the diffusion of neurochemicals from the extra- 
cellular fluid into the dialysis membrane, and vice 
versa (Hamberger et al., 1983; Imperato and Di 
Chiara, 1985; Westerink and Tuinte, 1986; Ben- 
veniste and Diemer, 1987). 
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However, in some of the previous studies in- 
volving continuous dialysis large diameter U- 
shaped ("loop" style) probes were used (West- 
erink and Tuinte, 1986; Reiriz et al., 1989), and 
these can cause considerable non-specific neural 
damage. Different style probes have been re- 
ported to have different effects on the stability of 
basal DA in dialysate over 2 days, the effect of 
tetrodotoxin (TTX) and low Ca 2÷ conditions on 
DA release, and the disruption of blood flow and 
glucose utilization seen in locations distant from 
the site of probe implantation (Westerink and de 
Vries, 1988; Benveniste and Hiittemeier, 1990; 
Santiago and Westerink, 1990). Therefore,  in ex- 
ploring the feasibility of within-subjects design 
microdialysis experiments, we thought it was im- 
portant also to characterize the effects of daily 
sampling from a chronically implanted, small-di- 
ameter, concentric-style probe. This type of probe 
causes much less non-specific damage than a 
U-shaped probe, and a unilateral placement 
avoids the symmetrical bilateral damage pro- 
duced by a transverse probe. The effects of 4 days 
of continuous dialysis on both basal and stimu- 
lated DA release were assessed. 
Methods 
Subjects 
The subjects were adult female Holtzman rats 
weighing 250-350 g. Animals were housed indi- 
vidually in wire, hanging cages with free access to 
food and water, in a light and temperature con- 
trolled room (lights on at 08:00 and off at 18:00 
h). 
Protocol 
Experiment 1. Continuous dialysis over 4 days: 
effects of repeated amphetamine treatment. Each 
animal was anesthetized with sodium pentobarbi- 
tal, supplemented with methoxyflurane, and a 
single concentric-style microdialysis probe was 
stereotaxically lowered into the corpus of the 
neostriatum. The dialysis probe had a 4.0-mm- 
long dialysis surface with an outer diameter of 
250 izm, and has been described in detail else- 
where (Robinson and Whishaw, 1988; Robinson 
and Camp, 1991). The dialysis probe was perma- 
nently fixed in place with skull screws and dental 
acrylic. After the dental acrylic had cured, the 
animal was transferred to a test chamber, and the 
inlet tubing was attached to a liquid swivel (Ins- 
tec) mounted on the end of a counter-balanced 
arm centered over the test chamber. The animal 
was connected to the swivel via a flexible tether 
constructed from model airplane control cable, 
and this was attached to an elastic harness lo- 
cated around the animal's torso. The animals 
were then left overnight, and the perfusion solu- 
tion was pumped continuously through the probe 
at 0.3 /M/min. The perfusion solution contained 
147 mM Na +, 4.0 mM K +, 2.3 mM Ca 2+ and 
155.6 mM CI-, pH 6.0. 
The next day (defined here as day 1) the 
syringe pump was set at 1.5 ~tl/min and 30-60 
min later at least 3 baseline samples of dialysate 
were collected over 20-min intervals. After this, 
half the animals received an i.p. injection of 2.0 
mg/kg  of D-amphetamine sulfate (weight of the 
salt), and half an injection of an equal volume of 
0.9% saline. Sample collection then continued for 
200 min. The pump was then turned down to 0.3 
iz l /min until the next day (day 2), when the 
entire procedure was repeated. This continued 
for 4 days, except on day 3 only basal values were 
quantified. On day 4 all animals were given 2.0 
m g /k g  of amphetamine (after basal samples were 
collected), including those animals that previously 
received saline. The animals were tested in pairs, 
consisting of 1 saline and 1 amphetamine pre- 
treated rat. 
At the completion of each experiment the dial- 
ysis tubing was cut close to the dental acrylic 
"cap",  the open ends sealed with epoxy, and the 
animals returned to their home cage. A few days 
later the animals received an overdose of sodium 
pentobarbital and were perfused through the 
heart with saline followed by 10% formalin, with 
the dialysis probe in place. The brains were cut 
frozen, stained with cresyl violet, and the sections 
examined to determine the exact location of the 
dialysis probe. 
Experiment 2. Continuous dialysis over 4 days: 
effects of repeated cocaine. The protocol for this 
experiment was exactly as described for Exp. 1, 
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except for the following modifications. (1) The 
dialysis probe was lowered via a chronically im- 
planted guide cannula, which was placed stereo- 
taxically above the striatum at least 2 weeks prior 
to a test session (Robinson and Camp, 1991). 
When the dialysis probe was lowered into the 
striatum via the guide cannula, the day before a 
test session, the animals were only briefly anes- 
thetized with methoxyflurane. (2) On days 1-3 
half the animals received 15 m g / k g  of cocaine 
HC1 (i.p., free base) instead of amphetamine,  and 
on day 4 all the animals received 15 m g / k g  of 
cocaine. (3) The perfusion solution consisted of 
145 mM NaCI, 2.7 mM KCI, 1.2 mM CaC12, 1.0 
mM MgC12 and 0.2 mM ascorbic acid, pH 7.3 
(Moghaddam and Bunney, 1989). 
Assay of dialysate and data analysis 
Dialysate samples were assayed within 20-40 
min after collection using high performance liq- 
uid chromatography with electrochemical detec- 
tion, as described in detail elsewhere (Robinson 
and Camp, 1990, 1991). 
Data  are included only for those animals in 
which the probe was located in the corpus of the 
neostriatum and for which data were obtained on 
all 4 days of testing. The concentration of each 
compound is expressed in fmol /min ,  and all val- 
ues were corrected for probe recovery (calculated 
in vitro at 37 °C). Note that in vitro recovery 
procedures do not provide an accurate estimate 
of the actual interstitial concentration of DA 
(Benveniste and Hansen,  1991; Morrison et al., 
1991) but were used here primarily to minimize 
experimental  error due to variation in recovery, 
attributable to variation in probe construction. 
Statistical analyses were conducted using a 
Macintosh II computer  and Systat 5.0 ® or 
StatView II  ® software. The effect of days of 
dialysis for the drug-treated groups (ampheta-  
mine and cocaine) was determined by application 
of a within-subjects design analysis of variance for 
each compound. Comparisons between the saline 
and drug pret reated groups (on day 4) were made 
using a between-within  analysis of variance for 
each compound. I f  the outcome of the analysis of 
variance warranted, pairwise comparisons were 
made using either the Fisher 's Least Significant 




Fig. 1 shows the average basal concentrations 
of DA, DOPAC,  homovanillic acid (HVA) and 
5-hydroxyindoleacetic acid (5-HIAA) in dialysate 
on each of the 4 days of testing in Exp. 1. There 
was no difference between amphetamine (n = 6) 
and saline pretreated rats (n = 5) in the basal 
concentrations of DA (F  = 1.05, P = 0.33), 
D O P A C  (F  = 0.36, P = 0.56), HVA ( F  = 0.71, P 
= 0.42) or 5 -HIAA ( F =  0.02, P =  0.90) across 
the 4 days of testing (2-way ANOVAs)  and, 
therefore, these groups were pooled to simplify 
data presentation and analysis in Fig. 1. 
Fig. 1 shows that in Exp. 1 there was a marked 
decrease in the basal concentrations of DOPAC 
and HVA in dialysate across the 4 days of testing 
(for DOPAC, F = 20.58, P < 0.0001; for HVA, 
F = 21.54, P < 0.0001). There  was a large de- 








DA DOPAC HVA 5-HIAA 
Fig. 1. The mean (+ SEM) basal concentrations of d0pamine 
(DA), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic 
acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA) in 
dialysate on each of 4 consecutive days of continuous dialysis 
in Exp. 1 (each day is represented by the columns numbered 
1-4, for each compound). Note that there is a different 
vertical axis for DA and the 3 monoamine metabolites (Met). 
For each compound: *, indicates day 1 values that differed 
significantly from all other days; ~:, indicates day 4 values that 
differed from day 2 values; (n = 11; statistics based on within- 
subjects ANOVAs followed by pairwise comparisons with 
Fisher's LSD tests where appropriate; see text). 
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crease in both of the DA metabolites between 
days 1 and 2 (P  < 0.05, Fisher's LSD test), and a 
further significant decrease between days 2 and 4 
( P <  0.05). The day 3 value was intermediate 
between days 2 and 4 (Fig. 1). In contrast, there 
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Fig. 2. The effect of 2,0 mg /kg  of D-amphetamine sulfate on the mean (5: SEM) concentration of DA (panel A), DOPAC (panel 
B), HVA (panel C) and 5-HIAA (panel D) in dialysate on days l, 2 and 4 after probe implantation ( "AMPH" groups). The "day 4: 
SAL-A" group represents animals that received saline on the first 3 days of dialysis (data not shown) and their response to 
amphetamine on day 4 of dialysis is illustrated here. The first 20 min interval represents the basal concentration of each compound 
(mean of 3 determinations), and each subsequent 20 rain interval represents successive samples obtained beginning immediately 
after the injection of  amphetamine (given when indicated by the arrow in each panel). Dopamine: the effect of amphetamine on 
DA' was significantly decreased on days 2 and 4, relative to day l; and the day 4 values were significantly lower than the day 2 
values (2-way ANOVAs with repeated measures on both factors, day X interval; see text). Two-way ANOVAs with only 1 repeated 
measure (interval) were used, to compare the AMPH and saline pretreated groups. When saline pretreated animals received 
aml~hetamine on the 4th day of dialysis they showed a significantly smaller increase in DA than did the "day 1: AMPH" group, but 
did not differ from either the "day 2: AMPH" or the "day 4: AMPH" groups. That is, the magnitude of the decrease in 
amphetamine-stimulated DA release (relative to "day h AMPH")  was just as great in saline pretreated animals as in animals that 
received amphetamine on all days of testing. DOPAC: amphetamine produced a decrease in the concentration of DOPAC in 
dial~sate on all days of dialysis (the main effect of interval was significant for all comparisons). An overall 2-way ANOVA with 
repeated measures on both factors (day X interval) was significant ( F  d = 12.86, P = 0.002, F i = 10.98, P < 0.0001, F i n t e r a c t i o  n = 6.38, 
P ,k 0.0001). As expected by the decrease in basal DOPAC, subsequent 2-way ANOVAs comparing each day showed that there 
were significant differences between day 1 vs. day 2 (F  d = 10.64, P = 0.022; F i n t e r a c t i o  n = 6.35, P < 0.0001), day 1 vs, day 4 
(F  d = 13.5, P = 0.014, F i n t e r a c t i o  n = 6.93, P < 0.0001) and day 2 vs. day 4 (F  d = 16.26, P = 0.01, F i n t e r a c t i o  n = 2.92, P = 0.006). The 
saline pretreated group also differed significantly from the "day 1: AMPH" group, F i n t e r a c t i o  n = 4.42, P < 0.0001). HVA: essentially 
the same pattern of group differences as seen for DOPAC were found for HVA (statistics not presented). 5-HIAA: the overall 
2-w'ay ANOVA with repeated measures on both factors did not result in a significant effect of day of dialysis (F  d = 0.75, P = 0.5) or 
a day X interval interaction ( F i n t e r a c t i o  n = 1.46, P = 0.12). The effect of interval was significant (F  i = 9.54, P < 0.0001), indicating 
that there was a small increase in 5-HIAA after amphetamine administration in all groups. The saline pretreated group did not 
differ from the amphetamine pretreated group at any time. 
4 days of  dialysis ( F  = 1.69, P = 0.19, within-sub- 
jects ANOVA),  and only a very small decrease in 
the basal concentration of 5 -HIAA in dialysate, 
which was not quite statistically significant ( F  = 
2.61, P = 0.07; although Fisher 's tests resulted in 
a significant difference between the day 4 value 
and the values obtained on days 1 and 2, P < 0.05; 
Fig. 1). 
Fig. 2 illustrates the time course of the effect 
of amphetamine  on the concentrations of DA, 
DOPAC, H V A  and 5 -HIAA on days 1, 2 and 4 of 
dialysis in those animals that received daily am- 
phetamine (n = 6), and on day 4 of testing in 
saline pret reated animals (n = 5). On day 1, am- 
phetamine produced a large increase in the con- 
centration of D A  in dialysate, as expected 
(Robinson and Camp, 1990). However, respon- 
siveness to amphetamine  was greatly at tenuated 
on all subsequent days of testing (overall 2-way 
A N O V A  with repeated measures on both factors, 
day and interval, Fd (effect of d a y ) =  19.8, P < 
0.0001, F i (day by interval in terac t ion)= 7.05, P 
< 0.0001). Fig. 2A shows that the effect of am- 
phetamine on dialysate D A  was significantly re- 
duced on both day 2 (F  d = 11.67, P = 0.019; F~ = 
5.71, P < 0.0001) and day 4 ( F  d = 24.4, P = 0.004; 
F~ = 12.13, P < 0.0001), relative to day 1. The day 
4 values were also significantly less than the day 2 
values ( F  d = 20.37, P = 0.006; F i = 2.21, P = 0.03). 
Furthermore,  when saline pret reated rats re- 
ceived amphetamine for the first time on day 4 
they showed a significantly smaller increase in 
DA than did those animals receiving am- 
phetamine for the first time on day 1 ( F i =  3.2, 
P<0 .002 ) ,  but did not differ from the am- 
phetamine pre t rea ted  group when the latter were 
tested on either days 2 or 4. 
Fig. 2B,C shows the typical amphetamine-in-  
duced decrease in the dialysate concentrations of  
D O P A C  and HVA, respectively. The progressive 
decline in basal D O P A C  and H V A  across the 4 
days of testing is clearly evident, as is the absence 
of any marked change in 5 -HIAA (Fig. 2D). 
It is interesting that the magnitude of the 
decline in amphetamine-st imulated D A  release 
over the 4 days of testing was predicted by the 
magnitude of the decrease in basal D O P A C  but 
was not related to changes in basal DA. This is 
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illustrated by correlational analyses of the change 
in basal DOPAC,  basal DA, and peak am- 
phetamine-st imulated D A  release between days 1 
and 4. The percent change in basal D O P A C  and 
peak amphetamine-st imulated DA release be- 
tween days 1 and 2, and between days 1 and 4, 
were strongly correlated (r  = + 0.835 and + 0.813, 
P < 0.01, respectively). However, there was no 
significant correlation between the change in ei- 
ther basal D O P A C  and basal DA (between days 
1 and 4, r =  +0.247) or basal DA and peak 
amphetamine-st imulated DA release (between 
days 1 and 4, r = +0.311). 
Experiment 2 
Fig. 3 shows the average basal concentrations 
of DA, DOPAC,  H V A  and 5-HIAA on each of 
the 4 days of dialysis in Exp. 2. There  was no 
difference between cocaine (n = 5) and saline 
(n = 4) pret reated animals in the basal concentra- 
tion of DA ( F  = 0.25, P = 0.63), DOPAC (F  = 
0.69, P = 0.43), H V A  ( F  = 2.29, P = 0.17) or 5- 
H I A A  ( F  = 0.35, P = 0.57) across the 4 days of 
testing (2-way ANOVAs),  and therefore, these 
groups were pooled to simplify data presentation 
and analysis in Fig. 3. 
Uet. 0A Basal Values: Experiment 2 





DA DOPAC HVA 5-HIAA 
Fig. 3. The mean (+SEM) basal concentrations of DA, 
DOPAC, HVA, and 5-HIAA in dialysate on each of 4 consec- 
utive days of continuous dialysis in Exp. 2 (days 1-4 are 
represented as described in Fig. 1). Note that there is a 
different vertical axis for DA and for the 3 monoamine 
metabolites (Met). For each compound: *, indicates day 1 
values that differed significantly from all other days; f, indi- 
cates day 4 values that differed from day 2 values; :[:, indicates 
that this day 1 value differed only from the day 3 and day 4 
values. (n = 9). See the text for presentation of statistics. 
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Fig. 3 shows that in Exp. 2 there was a marked 
decrease in the basal concentrations of  DOPAC 
and HVA in dialysate across the 4 days of testing 
(fo/" DOPAC,  F = 43.5, P < 0.0001; for HVA, 
F = 29.4, P < 0.0001). For DOPAC, there was a 
large decrease between days 1 and 2 (Fisher's 
LSD test, P < 0.05), and a further significant 
decrease between days 2 and 4 ( P  < 0.05). The 
day 3 value was intermediate. For HVA there 
was also a large decrease between days 1 and 2 
(P  < 0.05), and this appeared to be maximal (i.e., 
there was no difference between days 2, 3 and 4; 
see Fig. 3). In contrast, there was no decrease in 
the basal concentration of D A  across the 4 days 
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Fig. 4. The effect of  1 5 m g / k g  of cocaine ("Coc") on the mean  ( +  SEM) concentration of DA, DOPAC,  HVA and 5-HIAA in 
dialysate on days 1, 2 and 4 after probe implantation ("Coc" groups). The "day 4: Sal-Coc" group represents  animals that received 
saline on the first 3 days of dialysis, and their response to cocaine on day 4 of dialysis is shown here. The first 20 min interval 
represents the basal concentration of each compound (mean of 3 determinations),  and each subsequent  20 min interval represents 
successive samples obtained beginning immediately after the injection of cocaine (indicated by the arrows). Dopamine:  see text for 
presentat ion of statistics. Briefly, the day 1 values were significantly different from both the day 2 and the day 4 values, and the 
"day 4: Sal-Coc" group did not differ significantly from the "Coc"  group on any day of dialysis. DOPAC:  an overall 2-way A N O V A  
with repeated measures  on both factors (day and interval) was significant (F  d = 35.1, P < 0.0001; F i = 2.54, P = 0.029; V i n t e r a c t i o  n = 
2.46, P = 0.006), indicating that the extracellular concentration of D O P A C  decreased over days of dialysis. Subsequent  2-way 
ANOVAs  showed that there were significant differences between day l vs. day 2 (F  d = 20.13, P =  0.01; F i n t e r a c t i o  n = 2.45, 
P ~ 0.034), day 1 vs. day 4 (F  d = 60.4, P < 0.00]; F i n t e r a c t i o  n = 3.4, P = 0.006), and day 2 vs. day 4 (F  d = 20.6, P = 0.01; F i n t e r a c t i o  n = 
1.15, P = 0.36). The  saline pretreated animals also differed significantly from the "day 1: Coc" group (F  a = 22.7, P =  0.002, 
F i n t e r a c t i o  n = 1.34, P = 0.24), but  other comparisons were not significant. HVA: essentially the same pat tern of group differences as 
seen for D O P A C  were found for HVA,  except, the day 2 vs. day 4 comparison was not significant, and the saline pretreated 
animals did not differ from any other  group (statistics not shown). 5-HIAA: an overall A N O V A  with repeated measures  on both 
factors was significant (F  d = 10.97, P = 0.005; F i = 1.29, P = 0.23; V i n t e r a c t i o  n = 4.85, P = 0:001), indicating that 5-HIAA changed 
over days of dialysis. Subsequent  2-way ANOVAs  showed that there were no significant differences between day 1 and day 2 
(F  d = 0.5; Finteractio n = 1.43, P = 0.22), but day 1 did differ from day 4 (F  d = 45.5, P = 0.003), and day 2 differed from day 4 
(F  d = 13.36, P = 0.022). The "day 4: Sal-Coc" group did not differ significantly from any other group. 
of dialysis (Fig. 3), and in fact, basal DA was 
significantly higher on days 2, 3 and 4 than on day 
1 ( F =  4.88, P =  0.009; follow-up Fisher's LSD 
tests, P < 0.05). Relative to the DA metabolites, 
there was only a small change in the basal con- 
centration of 5-HIAA across the 4 days of testing, 
although in contrast to Exp. 1, it was statistically 
significant in this experiment (F=8.67,  P =  
0.0004). By day 4, 5-HIAA was significantly lower 
than on days 1 or 2, and the day 3 value was 
significantly lower than the day 1 value (P < 0.05). 
Note, however, as in Exp. 1, there was no differ- 
ence in 5-HIAA between days 1 and 2, which is 
when the most marked decrease in the DA 
metabolites occurred (Fig. 3). 
Fig. 4 illustrates the time course of the effect 
of cocaine on the concentrations of DA, DOPAC, 
HVA and 5-HIAA in dialysate on days 1, 2 and 4, 
in those animals that received daily cocaine, and 
on day 4 of testing in the saline pretreated ani- 
mals. Cocaine significantly enhanced the concen- 
tration of DA in dialysate on all days of testing, 
although the effect of cocaine changed over the 4 
days of testing (2-way ANOVA with repeated 
measures on both factors, day and time, F d = 
10.71, P = 0.005; F i = 1.95, P = 0.032). Fig. 4A 
shows that, in contrast to the decrease in the 
effectiveness of amphetamine seen in Exp. 1, 
there appeared to be a significant increase in the 
effectiveness of cocaine over days of dialysis in 
this experiment. The day 2 values were signifi- 
cantly greater than the day 1 values (F d = 13.31, 
P = 0.022), and the day 4 values were significantly 
different than the day 1 and the day 2 values (day 
1 vs. day 4: F d = 16.95, P =  0.015; day 2 vs. 4: 
F i --4.83, P =  0.001). Cocaine also significantly 
elevated DA in saline pretreated rats, but the 
response to cocaine in this group did not differ 
significantly from that in cocaine pretreated ani- 
mals on any day of testing (2-way ANOVAs). 
The apparent increase in the effectiveness of 
cocaine in elevating DA in dialysate (Fig. 4A) 
should be interpreted with caution, however, be- 
cause (1) the basal concentration of DA also 
increased over the 4 days of testing, and (2) the 
cocaine pretreated group did not differ from the 
saline pretreated group (Fig. 3). Thus, if the 
cocaine-induced elevation in DA is expressed as 
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a percent of baseline (data not shown) there is no 
statistically significant difference between the 4 
groups illustrated in Fig. 4A at any single point in 
time. Nevertheless, even when DA is expressed 
as a percent of baseline, there was clearly no 
decrease in the effect of cocaine over 4 days of 
continuous dialysis, as was the case for am- 
phetamine-stimulated DA release (compare Figs. 
2 and 4). 
Fig. 4B,C further illustrates the marked de- 
cline in the basal concentration of DOPAC and 
HVA over the 4 days of dialysis (for DOPAC, 
F d = 35.1, P < 0.0001; for HVA, F d = 8.49, P = 
0.011), and the modest change in 5-HIAA (Fig. 
4D). It can also be seen in Fig. 4C that acute 
cocaine administration did not produce the 
marked reduction in DA metabolites produced by 
amphetamine. 
Discussion 
Previous studies on the effects of continuous 
dialysis in the nigrostriatal DA system give the 
impression that this procedure is associated with 
a parallel decrease in the basal levels of both DA 
and DA metabolites in dialysate and in am- 
phetamine-stimulated DA release (Imperato and 
Di Chiara, 1985; Westerink and Tuinte, 1986). In 
the present study, however, the marked decline in 
DA metabolites and amphetamine-stimulated DA 
release seen over 4 days of continuous dialysis 
was not accompanied by a significant decrease in 
basal DA (also compare groups 2 and 4 in Table I 
of Osborne et al. (1990)). In addition, it was 
found that the magnitude of the decrease in 
amphetamine-stimulated DA release was pre- 
dicted by the magnitude of the decrease in basal 
DOPAC, but there was no significant correlation 
between the change in amphetamine-stimulated 
DA release and the change in basal DA. Thus, 
the present study establishes that the decrease in 
DA metabolites and amphetamine-stimulated DA 
release associated with a few days of continuous 
dialysis is not necessarily accompanied by compa- 
rable changes in basal DA. 
The d~crease in the concentration of com- 
pounds in dialysate associated with continuous 
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dialysis has usually been attributed to a decline in 
"recovery", secondary to gliosis-related changes 
in diffusion (Westerink and Tuinte, 1986; Ben- 
veniste and Diemer, 1987). It is unlikely, how- 
ever, that a relatively non-specific decline in "re- 
covery" caused by a glial "l~arrier" can account 
for the pattern of changes reported here, because 
this would be expected to influence basal DA, as 
well as DA metabolites and amphetamine-stimu- 
lated DA release. Furthermore, the difference 
between DA and its metabolites is probably not 
related to the fact that the latter are acids, be- 
cause in neither experiment reported here was 
there a change in basal 5-HIAA between days 1 
and 2 of testing, which is when basal DOPAC 
and HVA showed the greatest decline (also see 
Reiriz et al., 1989). Had the present experiment 
extended beyond 4 days, however, recovery of 
DA may have decreased due to the development 
of a glial "barrier", as suggested previously 
(Westerink and Tuinte, 1986; Benveniste and 
Diemer, 1987). This effect may have been seen 
soon after implantation of a dialysis probe in 
previous experiments because of a variety of 
methodological differences, including the size and 
type of dialysis probe, the perfusion medium and 
details of the experimental protocol. 
If the decrease in dialysate levels of DA 
metabolites and amphetamine-stimulated DA re- 
lease was not due to impaired diffusion, what did 
cause these effects? One possibility is that these 
measures reflect the integrity of the dopaminer- 
gic innervation to the striatum and, thus, the 
extent to which probe implantation damaged DA 
terminals. It follows, of course, that the basal 
concentration of DOPAC in dialysate provides a 
much better indicator of the integrity of the ni- 
grostriatal DA system than does the basal con- 
centration of DA. In fact, basal DA may be a 
particularly unreliable indicator of the integrity of 
the dopaminergic input to the striatum. This in- 
terpretation is supported by recent studies on the 
effects of striatal DA depletion induced by 6-hy- 
droxydopamine or methamphetamine on the con- 
centrations of DA and DA metabolites in 
dialysate (Robinson and Whishaw, 1988; Touchet 
and Bennett, 1989; Abercrombie et al., 1990; 
Castafieda et al., 1990; Robinson et al., 1990). 
These latter studies show that the basal concen- 
tration of DA in dialysate does not reflect the 
extent of damage to the nigrostriatal DA system 
until ~ 90-95% of the DA input to the striatum 
is destroyed, presumably because a number of 
compensatory neural adaptations to partial injury 
interact to normalize the basal extracellular con- 
centration of DA (Robinson et al., 1990; Zig- 
mond et al., 1990). On the other hand, the basal 
concentration of DOPAC in dialysate does accu- 
rately reflect the degree of denervation (Aber- 
crombie et al., 1990; Castafieda et al., 1990; 
Robinson et al., 1990 for review). 
Amphetamine is a potential neurotoxin, and 
high doses can produce a very long-lasting deple- 
tion in the postmortem tissue concentration of 
striatal DA due to the degeneration of DA termi- 
nals in the striatum (Ellison et al., 1978; Seiden 
and Ricaurte, 1987; Ryan et al., 1990). It is im- 
portant to consider, therefore, whether hypothe- 
sized damage to the nigrostriatal DA system re- 
flected by the decrease in amphetamine- 
stimulated DA release and DA metabolites seen 
on days 2, 3 and 4 after probe implantation could 
be due to exposure to amphetamine during the 
first test session. This is unlikely for a number of 
reasons. First, the dose of amphetamine used 
here was far below that usually required for am- 
phetamine neurotoxicity (Robinson and Becker, 
1986). This is not a strong argument, however, 
because it is possible that tissue already damaged 
by probe implantation is more susceptible to the 
neurotoxic effects of amphetamine (e.g., Phebus 
et al., 1991). It is important, therefore, that saline 
pretreated animals also showed a decrease in 
amphetamine-stimulated DA release, relative to 
animals that received amphetamine during the 
first test session and did not differ from am- 
phetamine pretreated animals tested on day 4. 
This is strong support for the idea that it was 
probe implantation, and not prior experience with 
amphetamine, that was responsible for the deficit. 
Lastly, a number of microdialysis studies using 
between-subjects designs have shown that prior 
amphetamine treatment does not decrease DA 
release, but increases the DA release induced by 
a subsequent challenge injection of amphetamine 
(Ichikawa, 1988; Robinson et al., 1988; Kazahaya 
et al., 1989; Patrick et al., 1991). It is most proba- 
ble, t he re fo re ,  tha t  the decrease  in 
amphetamine-stimulated DA release seen over 4 
days of continuous dialysis is primarily a conse- 
quence of probe-induced alterations in the in- 
tegrity of the nigrostriatal DA system, and does 
not reflect the influence of prior amphetamine 
treatment on DA neurotransmission. 
Another finding that deserves discussion con- 
cerns the difference in the effect of probe im- 
plantation on the ability of cocaine vs. am- 
phetamine to increase the concentration of DA 
in dialysate. Amphetamine-stimulated DA re- 
lease was progressively and markedly decreased 
over the 4 days of testing, but there was no 
decrease in the ability of cocaine to elevate DA 
over this same period of time. Unfortunately, it is 
difficult to directly compare these 2 experiments 
because a different perfusion medium was used 
in each (they were conducted 3 years apart). For 
example, the higher basal level of DA in Exp. 1 is 
probably because the perfusion medium used in 
Exp. 1 had a higher concentration of Ca 2÷ than 
that used in Exp. 2 (Westerink et al., 1988; 
Moghaddam and Bunney, 1989). However, am- 
phetamine and cocaine also have a very different 
mechanism of action, and there is reason to be- 
lieve this may be the critical variable. 
Cocaine acts primarily by binding to the DA 
transporter, preventing the reuptake of DA, but 
has little or no effect on DA release (Kuczenski, 
1983; Nicolaysen and Justice, 1988). Therefore, 
the accumulation of extracellular DA seen follow- 
ing cocaine is thought to originate from a vesicu- 
lar, readily releasable pool of DA by a Ca2÷-de - 
pendent release process (Hurd and Ungerstedt, 
1989) which is presumably due to the sponta- 
neous discharge of DA neurons. Although co- 
caine can inhibit the discharge of DA neurons by 
hyperpolarization, this action of cocaine seems to 
require a higher brain concentration of cocaine 
than is necessary to block reuptake and affect 
synaptic activity (Lacey et al., 1990; Uchimura 
and North, 1990). Thus, the elevation in extracel- 
lular DA produced by cocaine may be viewed 
simply as an accumulation of "basal" DA (i.e., 
that due to spontaneous release), due to reuptake 
blockade. Given that there was no decrease in 
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basal DA over the 4 days of dialysis and that 
cocaine simply produces an accumulation of basal 
DA, it is not surprising that the effect of cocaine 
did not change over this period of time either. 
Amphetamine, on the other hand, is a potent 
DA "releaser" (Kuczenski, 1983). Amphetamine 
is thought to release DA from a cytoplasmic pool 
of unbound DA by a Ca2÷-independent, exchange- 
diffusion process that requires ongoing DA syn- 
thesis (Fischer and Cho, 1979; Kuczenski, 1983; 
Justice et al., 1988), and this occurs independent 
of neuronal discharge and autoreceptor regula- 
tion (Kamal et al., 1981; Kuczenski et al., 1990). 
The marked decline in amphetamine-stimulated 
DA release seen between 2 and 4 days after 
probe implantation is presumably related, there- 
fore, to a disruption of some aspect(s) of this 
release process. The experiments reported here 
do not allow us to conclude, however, whether 
the decline in stimulated DA release is unique to 
amphetamine-stimulated DA release. It may not 
be, because Westerink and Tuinte (1986) re- 
ported that K+-stimulated DA release also de- 
creases between the day after probe implantation 
and the next day (although they used a relatively 
large U-shaped probe). Nevertheless, it appears 
that either following 2-4 days of chronic probe 
implantation, or following a second probe inser- 
tion at the same site (Camp and Robinson, 1991), 
DA systems are able to maintain basal extracellu- 
lar levels of DA but not  the demands for in- 
creased DA release imposed by an amphetamine 
challenge. The deficit in stimulated DA release 
may involve an inability to maintain DA synthe- 
sis, or some other aspect(s) of the biochemical 
cascade required for sustaining large amounts of 
releasable DA; and changes in other aspects of 
neurotransmission cannot be excluded at this 
time. It is certainly possible that complex interac- 
tions between many processes are involved, and 
determination of the exact nature of the deficit 
will require further experimentation. 
Whatever the reason for the deficit in am- 
phetamine-stimulated DA release,reported here, 
the results suggest that within-subjects design ex- 
periments involving continuous dialysis over a few 
days in DA systems probably should be avoided. 
The effects of repeated probe insertions at the 
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same site are very similar to those reported here, 
suggesting that this approach may not be appro- 
priate either (Camp and Robinson, 1991; Robin- 
son and Camp, 1991). Whether within-subjects 
designs are feasible for studying other neuro- 
transmitter systems, or animals with a larger brain 
(e.g., Kendrick, 1991), remain open questions. 
For example, the basal concentrations of aspar- 
tate, threonine and glutamate in dialysate from 
the substantia nigra of cats are reported to be 
stable over ten months (Delgado et al., 1984). On 
the other hand, Korf and Venema (1985) have 
reported that although some amino acids are 
stable over 9 days of dialysis, others are not, and 
the response to K ÷ changes over 9 days of dialy- 
sis. Of course, there is the question of the source 
of amino acids sampled with dialysis in brain, and 
it has been suggested that a significant proportion 
may not be of neural origin (Westerink and de 
Vries, 1989; Westerink et al., 1987, 1988, 1989). 
In conclusion, the experiments reported here 
suggest that with the technology presently avail- 
able within-subjects design studies involving con- 
tinuous microdialysis in the DA system of small 
animals are ill advised. If microdialysis is used for 
within-subjects design experiments, it should be 
incumbent upon the investigator to demonstrate 
that the integrity of the system under study is 
maintained between test sessions. Most impor- 
tantly, the data presented here establish that a 
"stable" concentration of a neurotransmitter in 
dialysate does not constitute such evidence, and 
in fact, this may be the least sensitive indicator of 
the integrity of a neurotransmitter system (Robin- 
son et al., 1990). 
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